PNPLA3基因变异、肥胖与大量饮酒在肝硬化患者中可能协同增加肝细胞癌风险
研究基于美国2项多中心前瞻性队列1911例肝硬化患者,分析PNPLA3 I148M变异、当前大量饮酒与肥胖对肝细胞癌(HCC)风险的独立及联合效应,采用竞争风险Cox回归。116例发生HCC。PNPLA3变异携带者合并当前大量饮酒者HCC风险较非携带者不饮酒者高2.65倍(HR 2.65,95%CI 1.20-5.86);携带者合并肥胖者较非携带者不肥胖者风险高(HR 2.40,95%CI 1.33-4.31)。PNPLA3可改善1年HCC风险预测。
要点
- PNPLA3变异携带合并当前大量饮酒者HCC风险较非携带不饮酒者高2.65倍(HR 2.65,95%CI 1.20-5.86)。
- PNPLA3变异携带合并肥胖者HCC风险较非携带不肥胖者高(HR 2.40,95%CI 1.33-4.31)。
- 病毒性病因肝硬化患者中PNPLA3与饮酒的联合效应更强(HR 3.42,95%CI 1.31-8.90)。
核心结论
- PNPLA3变异可能有助于细化合并大量饮酒或肥胖的肝硬化患者的HCC风险分层,这些患者可能需要特定预防措施。
研究设计与样本
- 美国2项多中心前瞻性队列研究,纳入1911例肝硬化患者,按当前大量饮酒与否、肥胖(BMI≥30 vs <30 kg/m2)及PNPLA3 I148M变异状态(携带至少一个G风险等位基因 vs 非携带)分类,采用竞争风险Cox回归分析HCC风险。
主要发现
- 平均年龄59.6岁,男性64.3%,西班牙裔28.7%,非西班牙裔黑人18.3%,肥胖50.9%,当前大量饮酒6.2%,携带至少1个PNPLA3 G等位基因58.4%。
- 116例患者发生HCC。
- 与非携带者且无大量饮酒者相比,携带者合并当前大量饮酒的HCC风险高2.65倍(HR 2.65;95%CI 1.20-5.86)。
- 与非携带者且无肥胖者相比,携带者合并肥胖的HCC风险更高(HR 2.40;95%CI 1.33-4.31)。
- 在病毒性病因肝硬化患者中,PNPLA3与饮酒的效应更强(HR 3.42;95%CI 1.31-8.90)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with cirrhosis, continued heavy alcohol consumption and obesity may increase risk of hepatocellular carcinoma (HCC). We examined whether germline susceptibility to hepatic steatosis not only independently predisposes to HCC but may also act synergistically with other risk factors. METHODS: We analyzed data from 1911 patients in 2 multicenter prospective cohort studies in the United States. We classified patients according to alcohol consumption (current heavy vs not current heavy), obesity (body mass index ≥30 vs <30 kg/m2), and PNPLA3 I148M variant status (carrier of at least one G risk allele vs noncarrier). We examined the independent and joint effects of these risk factors on risk of developing HCC using Cox regression with competing risks. RESULTS: Mean age was 59.6 years, 64.3% were male, 28.7% were Hispanic, 18.3% were non-Hispanic Black, 50.9% were obese, 6.2% had current heavy alcohol consumption, and 58.4% harbored at least 1 PNPLA3 G-allele. One hundred sixteen patients developed HCC. Compared with PNPLA3 noncarriers without heavy alcohol consumption, HCC risk was 2.65-fold higher (hazard ratio [HR], 2.65; 95% confidence interval [CI], 1.20-5.86) for carriers who had current heavy alcohol consumption. Compared with noncarrier patients without obesity, HCC risk was higher (HR, 2.40; 95% CI, 1.33-4.31) for carrier patients who were obese. PNPLA3 and alcohol consumption effect was stronger among patients with viral etiology of cirrhosis (HR, 3.42; 95% CI, 1.31-8.90). PNPLA3 improved 1-year risk prediction for HCC when added to a clinical risk model. CONCLUSIONS: The PNPLA3 variant may help refine risk stratification for HCC in patients with cirrhosis with heavy alcohol consumption or obesity who may need specific preventive measures.
引用
- Thrift AP, Kanwal F, Lim H, et al. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024. PMID: 38729396. doi:10.1016/j.cgh.2024.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。